ImmunoGen Listed a New Clinical Trial of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression

Press/Media

Period24 Dec 2019

Media coverage

1

Media coverage

  • TitleImmunoGen Listed a New Clinical Trial of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression
    Media name/outletIndia Pharma News
    Country/TerritoryIndia
    Date24/12/19
    PersonsSharyn Lewin